Total Live Articles: 471

COVID-19

NICE guideline [NG191] COVID-19 rapid guideline: managing COVID-19. Last updated: May 2025.

UK Health Security Agency Guidance COVID-19: epidemiology, virology and clinical features. Last updated: May 2022.

COVID-19

Virology

COVID is caused by infection with the SARS-CoV-2 virus, an RNA virus that belongs to the coronavirus family.

Transmission

COVID-19 is mainly transmitted through infectious respiratory particles (droplets and aerosols)

  • The SARS-CoV-2 virus-containing respiratory particles are released when someone with COVID-19 speaks / coughs / sneezes
  • Another person can catch COVID-19 when these particles are inhaled or come into contact with the eye / nose / mouth

Indirect transmission can occur through contact with surfaces contaminated with the virus (fomite transmission).

Clinical Features

Patients present with varying severity of symptoms; 1 in 3 patients are asymptomatic.

Main symptoms of COVID-19:

  • Fever
  • New and continuous cough
  • Loss of smell (anosmia)
  • Loss of taste (ageusia)

Other symptoms include:

  • Dyspnoea
  • Fatigue
  • Loss of appetite
  • Myalgia
  • Sore throat
  • Headache
  • Nasal congestion / runny nose

Severe Illness

NICE noted that the following suggest COVID-19 with the most severe illness:

  • Severe shortness of breath at rest or difficulty breathing
  • Reduced oxygen saturation levels measured by pulse oximetry
  • Coughing up blood
  • Blue lips or face
  • Feeling cold and clammy with pale or mottled skin
  • Collapse or fainting (syncope)
  • New confusion
  • Becoming difficult to rouse
  • Reduced urine output

Investigation and Diagnosis

Recommended diagnostic samples for suspected cases:

Upper respiratory tract sample (usually preferred) ANY of the following:

  • Single swab used for throat, then nose
  • Combined nose and throat swab
  • Nasopharyngeal aspirate
Lower respiratory tract sample Sputum (if obtainable)

Testing method:

  • Lateral flow test – quick, less sensitive screening tool
  • RT-PCR – diagnostic gold standard

Management

Pharmacological therapy options for COVID-19:

Drug class Drug Indication / criteria
Antivirals Nirmatrelvir plus ritonavir
  • Adults who do NOT require supplemental oxygen, and
  • At risk of severe COVID-19
Remdesivir
  • Adults at risk of severe COVID-19

For paediatrics, click to see indications

Molnupiravir
  • Nirmatrelvir plus ritonavir is contraindicated / unsuitable, AND
  • Mild to moderate COVID-19, and
  • At risk of severe COVID-19
Corticosteroid Dexamethasone (alternative: hydrocortisone, prednisolone)
  • Patients who need oxygen therapy (including those who are unable to tolerate it)

Continue for up to 10 days unless there is a clear indication to stop early

NICE explicitly mentioned NOT to use corticosteroids in COVID-19 patients who do NOT need supplemental oxygen

Immunomodulators Tocilizumab (IL-6 inhibitor)
  • Adults receiving systemic corticosteroids, and
  • Need supplemental oxygen or mechanical ventilation
Baricitinib (JAK inhibitor)
  • Considered in patients aged 2 years and over in hospital who need supplemental oxygen, and
  • Receiving systemic corticosteroids (or have completed a course), and
  • Have no evidence of infection (other than SARS-CoV-2) that might be worsened by baricitinib

NICE explicitly mentioned NOT to use the following treatments for COVID-19

  • Antibiotics (including azithromycin and doxycycline) – unless there is evidence of bacterial co-infection
  • Colchicine
  • Inhaled budesonide (only use as part of a clinical trial)
  • Ivermectin (only use as part of a clinical trial)
  • Vitamin D (only used as part of a clinical trial)

References

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.